Stifel Financial Corp Intellia Therapeutics, Inc. Transaction History

Stifel Financial Corp

$99.8 Billion
Q2 2025

A detailed history of Stifel Financial Corp transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 785,034 shares of NTLA stock, worth $22 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

785,034

Previous 789,662 0.59%

Holding current value

$22 Million

Previous $5.61 Million 31.15%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.28 - $9.67 $29,063 - $44,752	-4,628 Reduced 0.59%	785,034 $7.36 Million
Q1 2025 May 13, 2025	BUY	$7.11 - $12.8 $2.79 Million - $5.02 Million	391,901 Added 98.53%	789,662 $5.61 Million
Q4 2024 Feb 13, 2025	BUY	$11.41 - $21.09 $3.46 Million - $6.39 Million	303,151 Added 320.42%	397,761 $4.64 Million
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $61,171 - $84,870	3,102 Added 3.39%	94,610 $1.94 Million
Q2 2024 Aug 13, 2024	BUY	$20.02 - $27.22 $148,468 - $201,863	7,416 Added 8.82%	91,508 $2.05 Million
Q1 2024 May 13, 2024	BUY	$23.82 - $32.8 $370,853 - $510,663	15,569 Added 22.72%	84,092 $2.31 Million
Q4 2023 Feb 12, 2024	BUY	$23.16 - $32.34 $433,879 - $605,857	18,734 Added 37.63%	68,523 $2.09 Million
Q3 2023 Nov 13, 2023	BUY	$31.62 - $45.78 $201,956 - $292,396	6,387 Added 14.72%	49,789 $1.57 Million
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $436,295 - $580,760	12,617 Added 40.98%	43,402 $1.77 Million
Q1 2023 May 12, 2023	BUY	$33.3 - $44.82 $14,318 - $19,272	430 Added 1.42%	30,785 $1.15 Million
Q4 2022 Feb 13, 2023	BUY	$33.21 - $62.69 $168,374 - $317,838	5,070 Added 20.05%	30,355 $1.06 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $55,429 - $73,707	1,028 Added 4.24%	25,285 $1.42 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $234,327 - $463,966	6,088 Added 33.51%	24,257 $1.26 Million
Q1 2022 May 13, 2022	SELL	$58.27 - $118.99 $93,523 - $190,978	-1,605 Reduced 8.12%	18,169 $1.32 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $35,165 - $48,287	-349 Reduced 1.73%	19,774 $2.34 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $425,304 - $567,994	-3,213 Reduced 13.77%	20,123 $2.7 Million
Q2 2021 Aug 13, 2021	SELL	$60.88 - $161.91 $316,636 - $842,093	-5,201 Reduced 18.23%	23,336 $3.78 Million
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $488,123 - $876,715	10,477 Added 58.01%	28,537 $2.29 Million
Q4 2020 Feb 12, 2021	BUY	$18.83 - $63.53 $340,069 - $1.15 Million	18,060 New	18,060 $982,000
Q4 2018 Feb 13, 2019	SELL	$11.39 - $27.13 $92,543 - $220,431	-8,125 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$25.78 - $32.6 $209,462 - $264,875	8,125 New	8,125 $234,000

Others Institutions Holding NTLA

# of Institutions

333

Shares Held

97M

Call Options Held

1.66M

Put Options Held

1.03M

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $2.13B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp Intellia Therapeutics, Inc. Transaction History